SI-BONE 3Q 2026: Revenue $55.7M, Net income ($3.62M), EPS ($0.08) — 10-Q Summary

What happened

SI-BONE reported third-quarter 2026 revenue of $55.7 million, up 14.5% from a year earlier. Its net loss narrowed to $3.62 million from $4.57 million, and diluted loss per share improved to $0.08 from $0.11. Procedure volume grew 19.5%.

Confirmed

Global impact / market context

Revenue and procedure growth suggest SI-BONE is expanding sales activity, while the narrower loss indicates progress toward reducing the gap between income and costs. However, the company still reported a loss, so continued growth and cost control matter for its path toward profitability.

Analyst inference

The reported growth came alongside a larger sales network and rising revenue per territory manager, suggesting stronger selling capacity. More procedures in outpatient settings may broaden where care is delivered, but the article does not provide forecasts, cash available, or valuation information.

Analyst inference

What to watch

1. Check whether revenue and procedure growth continue in later quarters, since sustained increases would show that recent expansion is translating into ongoing demand. Analyst inference
2. Watch whether the net loss narrows further; continued losses mean costs still exceed income, and a reversal could weaken progress toward profitability. Analyst inference
3. Track developments in next-generation products, clinical and regulatory initiatives, and expansion into spinopelvic fixation and trauma, which the article identifies as research and development priorities. Confirmed

Evidence

• Original source link unavailable